Abstract
Tetrahydrobiopterin (H4-biopterin) is an essential cofactor of a set of enzymes that are of central metabolic importance, i.e. the hydroxylases of the three aromatic amino acids phenylalanine, tyrosine, and tryptophan, of ether lipid oxidase, and of the three nitric oxide synthase (NOS) isoenzymes. As a consequence, H4-biopterin plays a key role in a vast number of biological processes and pathological states associated with neurotransmitter formation, vasorelaxation, and immune response. In mammals, its biosynthesis is controlled by hormones, cytokines and certain immune stimuli. This review aims to summarize recent developments concerning regulation of H4-biopterin biosynthetic and regulatory enzymes and pharmacological effects of H4-biopterin in various conditions, e.g. endothelial dysfunction or apoptosis of neuronal cells. Also, approaches towards gene therapy of diseases like the different forms of phenylketonuria or of Parkinsons disease are reviewed. Additional emphasis is given to H4-biopt erin biosynthesis and function in non-mammalian species such as fruit fly, zebra fish, fungi, slime molds, the bacterium Nocardia as well as to the parasitic protozoan genus of Leishmania that is not capable of pteridine biosynthesis but has evolved a sophisticated salvage network for scavenging various pteridine compounds, notably folate and biopterin.
Keywords: Tetrahydrobiopterin biosynthesis, Nitric oxide synthase(nos), leishmania, H-biopterin deficiencies, Primitive eukaryotes, Physarum polycephalum, Sepiapterin reductase, Dihydro pteridine reductase
Current Drug Metabolism
Title: Tetrahydrobiopterin Biosynthesis, Utilization and Pharmacological Effects
Volume: 3 Issue: 2
Author(s): G. Werner-Felmayer, G. Golderer and E. R. Werner
Affiliation:
Keywords: Tetrahydrobiopterin biosynthesis, Nitric oxide synthase(nos), leishmania, H-biopterin deficiencies, Primitive eukaryotes, Physarum polycephalum, Sepiapterin reductase, Dihydro pteridine reductase
Abstract: Tetrahydrobiopterin (H4-biopterin) is an essential cofactor of a set of enzymes that are of central metabolic importance, i.e. the hydroxylases of the three aromatic amino acids phenylalanine, tyrosine, and tryptophan, of ether lipid oxidase, and of the three nitric oxide synthase (NOS) isoenzymes. As a consequence, H4-biopterin plays a key role in a vast number of biological processes and pathological states associated with neurotransmitter formation, vasorelaxation, and immune response. In mammals, its biosynthesis is controlled by hormones, cytokines and certain immune stimuli. This review aims to summarize recent developments concerning regulation of H4-biopterin biosynthetic and regulatory enzymes and pharmacological effects of H4-biopterin in various conditions, e.g. endothelial dysfunction or apoptosis of neuronal cells. Also, approaches towards gene therapy of diseases like the different forms of phenylketonuria or of Parkinsons disease are reviewed. Additional emphasis is given to H4-biopt erin biosynthesis and function in non-mammalian species such as fruit fly, zebra fish, fungi, slime molds, the bacterium Nocardia as well as to the parasitic protozoan genus of Leishmania that is not capable of pteridine biosynthesis but has evolved a sophisticated salvage network for scavenging various pteridine compounds, notably folate and biopterin.
Export Options
About this article
Cite this article as:
Werner-Felmayer G., Golderer G. and Werner R. E., Tetrahydrobiopterin Biosynthesis, Utilization and Pharmacological Effects, Current Drug Metabolism 2002; 3 (2) . https://dx.doi.org/10.2174/1389200024605073
DOI https://dx.doi.org/10.2174/1389200024605073 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
Call for Papers in Thematic Issues
Impact of brain tissue binding and plasma protein binding of drugs in DMPK
The impression of brain tissue binding (BTB) or plasma protein binding (PPB) in Drug Metabolism and Pharmacokinetics is critical to understanding the distribution, efficacy, and potential toxicity of drugs that target the central nervous system (CNS). BTB and high PPB influence the distribution of drugs in the body and their ...read more
Interaction between drugs and endocrine diseases
The introduction of highly active antiretroviral therapy accelerated studies and our understanding on the interaction between pharmacological therapies and endocrine diseases. Drugs can precipitate endocrine via different mechanisms, including direct alteration of hormone production and secretion, dysregulation of hormonal axis, effects on hormonal transport, receptor-binding, and cellular signalling. Common drug-induced ...read more
Metabolism-Mediated Xenobiotic Toxicity
Considering the potent modulation of biotransformation enzyme expression and activities by various therapeutic drugs and environmental chemicals, and the commonly combined exposure of humans to both drugs and the ever increasing environmental pollutants simultaneously, knowledge about the combined toxic effects by modulating biotransformation enzymes, such as P450s, UDP- glucuronosyltransferases, and ...read more
Safety evaluation of vaccine combination
Vaccine combination safety evaluation is a critical field within immunology and public health that focuses on assessing the safety and efficacy of combining different vaccines to maximize protection against various diseases while minimizing potential adverse effects. This process is significant because it ensures that vaccines can be administered together without ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lipoprotein-Related and Apolipoprotein-Mediated Delivery Systems for Drug Targeting and Imaging
Current Medicinal Chemistry Idronoxil as an Anticancer Agent: Activity and Mechanisms
Current Cancer Drug Targets Role of CYP2E1 in Mitochondrial Dysfunction and Hepatic Injury by Alcohol and Non-Alcoholic Substances
Current Molecular Pharmacology Engagement of Renin-Angiotensin System in Prostate Cancer
Current Cancer Drug Targets Meet Our Co-Editor
Current Signal Transduction Therapy Impact of MCP -1 in Atherosclerosis
Current Pharmaceutical Design p38 MAP Kinase Interacts with and Stabilizes Pancreatic and Duodenal Homeobox-1
Current Molecular Medicine Targeting Chromatin Remodeling for Cancer Therapy
Current Molecular Pharmacology GPRASP/ARMCX Protein Family: Potential Involvement in Health and Diseases Revealed by their Novel Interacting Partners
Current Topics in Medicinal Chemistry Regional Differences in Adaptation of CNS Mu Opioid Receptors to Chronic Opioid Agonist Administration
Current Neuropharmacology Therapeutic Window, a Critical Developmental Stage for Stem Cell Therapies
Current Stem Cell Research & Therapy Compounds From Celastraceae Targeting Cancer Pathways and Their Potential Application in Head and Neck Squamous Cell Carcinoma: A Review
Current Genomics Conventional and Gene Therapy Strategies for the Treatment of Brain Tumors
Current Medicinal Chemistry Targeting Options of Tumor-Associated Macrophages (TAM) Activity in Gliomas
Current Neuropharmacology Interleukin-15 in Gene Therapy of Cancer
Current Gene Therapy Blood-Brain Barrier Penetration and Drug Development from an Industrial Point of View
Current Medicinal Chemistry - Central Nervous System Agents Preservation of Cellular Glutathione Status and Mitochondrial Membrane Potential by N-Acetylcysteine and Insulin Sensitizers Prevent Carbonyl Stress-Induced Human Brain Endothelial Cell Apoptosis
Current Neurovascular Research Optimization of the Enzymolysis Conditions for Scorpion Peptides and Evaluation of its Antitumor Activity
Current Signal Transduction Therapy Viral Hybrid-Vectors for Delivery of Autonomous Replicons
Current Gene Therapy The Heat Shock Protein 90 Chaperone Complex: An Evolving Therapeutic Target
Current Cancer Drug Targets